Detalles de la búsqueda
1.
Pomalidomide plus dexamethasone for patients with relapsed or refractory multiple myeloma: Final results of the non-interventional study POSEIDON and comparison with the pivotal phase 3 clinical trials.
Eur J Haematol
; 108(2): 133-144, 2022 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-34714555
2.
Rare lymphomas in routine practice - Treatment and outcome in marginal zone lymphoma in the prospective German Tumour Registry Lymphatic Neoplasms.
Hematol Oncol
; 39(3): 313-325, 2021 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-33942348
3.
Rare lymphomas in routine practice-Treatment and outcome in Waldenström's macroglobulinaemia in the prospective German Tumour Registry Lymphatic Neoplasms.
Hematol Oncol
; 38(3): 344-352, 2020 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-32383192
4.
First-line therapy with bendamustine/prednisone/bortezomib-A GMMG trial for non-transplant eligible symptomatic multiple myeloma patients.
Eur J Haematol
; 105(2): 116-125, 2020 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-32155662
5.
Real-world treatment patterns and outcomes in non-transplant newly diagnosed multiple Myeloma in France, Germany, Italy, and the United Kingdom.
Eur J Haematol
; 105(3): 308-325, 2020 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-32418256
6.
Similar effectiveness of R-CHOP-14 and -21 in diffuse large B-cell lymphoma-data from the prospective German Tumour Registry Lymphatic Neoplasms.
Eur J Haematol
; 103(5): 460-471, 2019 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-31314918
7.
Bendamustine, followed by obinutuzumab and idelalisib in chronic lymphocytic leukemia (CLL2-BCG): Final analysis of a multicenter, open-label phase-II-trial.
Am J Hematol
; 99(6): 1192-1195, 2024 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-38578022
8.
Survival of non-transplant patients with multiple myeloma in routine care differs from that in clinical trials-data from the prospective German Tumour Registry Lymphatic Neoplasms.
Ann Hematol
; 97(12): 2437-2445, 2018 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-30069704
9.
Bendamustine, lenalidomide and dexamethasone (BRd) has high activity as 2nd -line therapy for relapsed and refractory multiple myeloma - a phase II trial.
Br J Haematol
; 176(5): 770-782, 2017 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-27983764
10.
Diagnosis and treatment of multiple myeloma in Germany: analysis of a nationwide multi-institutional survey.
Ann Hematol
; 96(6): 987-993, 2017 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-28409228
11.
Bortezomib and low-dose dexamethasone with or without continuous low-dose oral cyclophosphamide for primary refractory or relapsed multiple myeloma: a randomized phase III study.
Ann Hematol
; 96(11): 1857-1866, 2017 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-28905189
12.
Routine treatment of patients with chronic lymphocytic leukaemia by office-based haematologists in Germany-data from the Prospective Tumour Registry Lymphatic Neoplasms.
Hematol Oncol
; 33(1): 15-22, 2015 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-24733536
13.
Early autologous stem cell transplantation for chronic lymphocytic leukemia: long-term follow-up of the German CLL Study Group CLL3 trial.
Blood
; 119(21): 4851-9, 2012 May 24.
Artículo
en Inglés
| MEDLINE | ID: mdl-22490331
14.
Ambulatory Routine Care in Oncology in Germany: Real-World Survival Data.
Oncol Res Treat
; : 1-11, 2024 Mar 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-38493778
15.
Prioritization and Resource Allocation in the Context of the COVID-19 Pandemic: Recommendations for Colorectal and Pancreatic Cancer in Germany.
Oncol Res Treat
; 47(6): 296-305, 2024.
Artículo
en Inglés
| MEDLINE | ID: mdl-38484712
16.
Bendamustine compared to fludarabine as second-line treatment in chronic lymphocytic leukemia.
Ann Hematol
; 92(5): 653-60, 2013 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-23340738
17.
Real-world clinical effectiveness and safety of CT-P10 in patients with diffuse large B-cell lymphoma: An observational study in Europe.
EJHaem
; 4(1): 45-54, 2023 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-36819165
18.
Bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukaemia: updated results of a randomized phase III trial.
Br J Haematol
; 159(1): 67-77, 2012 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-22861163
19.
Results of a Prospective Non-Interventional Post-Authorization Safety Study of Idelalisib in Germany.
Clin Lymphoma Myeloma Leuk
; 22(8): e777-e787, 2022 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-35624058
20.
Addition of isatuximab to lenalidomide, bortezomib, and dexamethasone as induction therapy for newly diagnosed, transplantation-eligible patients with multiple myeloma (GMMG-HD7): part 1 of an open-label, multicentre, randomised, active-controlled, phase 3 trial.
Lancet Haematol
; 9(11): e810-e821, 2022 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-36328040